Impact of Antibiotic-Resistant Bacteria on the Outcome of Ventilator-Associated Pneumonia

 

 Buy Article Permissions and Reprints

ABSTRACT

Since antibiotic resistance has become a worldwide concern, there has been an ongoing debate as to whether infections caused by resistant bacteria are associated with higher mortality. Because resistant strains do not appear to be more virulent, differences in outcome may principally relate to patients' characteristics before or at the time of infection onset, and to high rates of inappropriate empirical antimicrobial treatment prescribed for antibiotic-resistant infections. In two large series of severe Staphylococcus aureus and Pseudomonas aeruginosa ventilator-associated pneumonia, we recently demonstrated that antibiotic resistance does not significantly affect intensive care unit mortality of patients receiving appropriate initial antibiotics. However, antibiotic resistance was consistently found to increase hospital length of stay. Early identification of patients with risk factors favoring antibiotic-resistant infections should prompt the initiation of an empirical antibiotic regimen covering these highly resistant bacteria, which can usually be deescalated 48 to 72 hours later when the results of microbiological samples culture become available.

REFERENCES

• 1 Jevons M P. Celbin-resistant staphylococci.  BMJ. 1961;  1 124-125
  PubMedGoogle Scholar
• 2 National Nosocomial Infections Surveillance (NNIS) System Report . Data summary from January 1992 through June 2004, issued October 2004.  Am J Infect Control. 2004;  32 470-485
  CrossrefPubMedGoogle Scholar
• 3 Chastre J, Trouillet J L. Problem pathogens (Pseudomonas aeruginosa and Acinetobacter).  Semin Respir Infect. 2000;  15 287-298
  PubMedGoogle Scholar
• 4 Romero-Vivas J, Rubio M, Fernandez C et al.. Mortality associated with nosocomial bacteremia due to methicillin-resistant Staphylococcus aureus .  Clin Infect Dis. 1995;  21 1417-1423
  CrossrefPubMedGoogle Scholar
• 5 Pujol M, Pena C, Pallares R et al.. Nosocomial Staphylococcus aureus bacteremia among nasal carriers of methicillin-resistant and methicillin-susceptible strains.  Am J Med. 1996;  100 509-516
  CrossrefPubMedGoogle Scholar
• 6 Steinberg J P, Clark C C, Hackman B O. Nosocomial and community-acquired Staphylococcus aureus bacteremias from 1980 to 1993: impact of intravascular devices and methicillin resistance.  Clin Infect Dis. 1996;  23 255-259
  PubMedGoogle Scholar
• 7 Rello J, Torres A, Ricart M et al.. Ventilator-associated pneumonia by Staphylococcus aureus: comparison of methicillin-resistant and methicillin-sensitive episodes.  Am J Respir Crit Care Med. 1994;  150 1545-1549
  CrossrefPubMedGoogle Scholar
• 8 Blot S I, Vandewoude K H, Hoste E A et al.. Outcome and attributable mortality in critically ill patients with bacteremia involving methicillin-susceptible and methicillin-resistant Staphylococcus aureus .  Arch Intern Med. 2002;  162 2229-2235
  CrossrefPubMedGoogle Scholar
• 9 Talon D, Woronoff-Lemsi M C, Limat S et al.. The impact of resistance to methicillin in Staphylococcus aureus bacteremia on mortality.  Eur J Intern Med. 2002;  13 31-36
  PubMedGoogle Scholar
• 10 Engemann J J, Carmeli Y, Cosgrove S E et al.. Adverse clinical and economic outcomes attributable to methicillin resistance among patients with Staphylococcus aureus surgical site infection.  Clin Infect Dis. 2003;  36 592-598
  CrossrefPubMedGoogle Scholar
• 11 Cosgrove S E, Sakoulas G, Perencevich E N et al.. Comparison of mortality associated with methicillin-resistant and methicillin-susceptible Staphylococcus aureus bacteremia: a meta-analysis.  Clin Infect Dis. 2003;  36 53-59
  PubMedGoogle Scholar
• 12 Harbarth S, Rutschmann O, Sudre P et al.. Impact of methicillin resistance on the outcome of patients with bacteremia caused by Staphylococcus aureus .  Arch Intern Med. 1998;  158 182-189
  CrossrefPubMedGoogle Scholar
• 13 Tumbarello M, De Gaetano Donati K, Tacconelli E et al.. Risk factors and predictors of mortality of methicillin-resistant Staphylococcus aureus (MRSA) bacteraemia in HIV-infected patients.  J Antimicrob Chemother. 2002;  50 375-382
  CrossrefPubMedGoogle Scholar
• 14 Soriano A, Martinez J A, Mensa J et al.. Pathogenic significance of methicillin resistance for patients with Staphylococcus aureus bacteremia.  Clin Infect Dis. 2000;  30 368-373
  CrossrefPubMedGoogle Scholar
• 15 Mylotte J M, Tayara A. Staphylococcus aureus bacteremia: predictors of 30-day mortality in a large cohort.  Clin Infect Dis. 2000;  31 1170-1174
  CrossrefPubMedGoogle Scholar
• 16 French G L, Cheng A F, Ling J M et al.. Hong Kong strains of methicillin-resistant and methicillin-sensitive Staphylococcus aureus have similar virulence.  J Hosp Infect. 1990;  15 117-125
  CrossrefPubMedGoogle Scholar
• 17 Selvey L A, Whitby M, Johnson B. Nosocomial methicillin-resistant Staphylococcus aureus bacteremia: is it any worse than nosocomial methicillin-sensitive Staphylococcus aureus bacteremia?.  Infect Control Hosp Epidemiol. 2000;  21 645-648
  CrossrefPubMedGoogle Scholar
• 18 Raymond D P, Pelletier S J, Crabtree T D et al.. Impact of antibiotic-resistant gram-negative bacilli infections on outcome in hospitalized patients.  Crit Care Med. 2003;  31 1035-1041
  PubMedGoogle Scholar
• 19 Trouillet J L, Vuagnat A, Combes A et al.. Pseudomonas aeruginosa ventilator-associated pneumonia: comparison of episodes due to piperacillin-resistant versus piperacillin-susceptible organisms.  Clin Infect Dis. 2002;  34 1047-1054
  CrossrefPubMedGoogle Scholar
• 20 Blot S, Vandewoude K, De Bacquer D et al.. Nosocomial bacteremia caused by antibiotic-resistant gram-negative bacteria in critically ill patients: clinical outcome and length of hospitalization.  Clin Infect Dis. 2002;  34 1600-1606
  CrossrefPubMedGoogle Scholar
• 21 Carmeli Y, Troillet N, Karchmer A W et al.. Health and economic outcomes of antibiotic resistance in Pseudomonas aeruginosa .  Arch Intern Med. 1999;  159 1127-1132
  PubMedGoogle Scholar
• 22 Cosgrove S E, Kaye K S, Eliopoulous G M et al.. Health and economic outcomes of the emergence of third-generation cephalosporin resistance in Enterobacter species.  Arch Intern Med. 2002;  162 185-190
  CrossrefPubMedGoogle Scholar
• 23 Bjorkman J, Nagaev I, Berg O G et al.. Effects of environment on compensatory mutations to ameliorate costs of antibiotic resistance.  Science. 2000;  287 1479-1482
  CrossrefPubMedGoogle Scholar
• 24 Hewitt J H, Sanderson P J. The effect of methicillin on skin lesions in guinea-pigs caused by methicillin-sensitive and methicillin-resistant Staphylococcus aureus .  J Med Microbiol. 1974;  7 223-235
  PubMedGoogle Scholar
• 25 Peacock Jr J E, Moorman D R, Wenzel R P et al.. Methicillin-resistant Staphylococcus aureus: microbiologic characteristics, antimicrobial susceptibilities, and assessment of virulence of an epidemic strain.  J Infect Dis. 1981;  144 575-582
  PubMedGoogle Scholar
• 26 Aathithan S, Dybowski R, French G L. Highly epidemic strains of methicillin-resistant Staphylococcus aureus not distinguished by capsule formation, protein A content or adherence to HEp-2 cells.  Eur J Clin Microbiol Infect Dis. 2001;  20 27-32
  PubMedGoogle Scholar
• 27 Schmitz F J, MacKenzie C R, Geisel R et al.. Enterotoxin and toxic shock syndrome toxin-1 production of methicillin resistant and methicillin sensitive Staphylococcus aureus strains.  Eur J Epidemiol. 1997;  13 699-708
  CrossrefPubMedGoogle Scholar
• 28 Laurent F, Lelievre H, Cornu M et al.. Fitness and competitive growth advantage of new gentamicin-susceptible MRSA clones spreading in French hospitals.  J Antimicrob Chemother. 2001;  47 277-283
  CrossrefPubMedGoogle Scholar
• 29 Duckworth G J, Jordens J Z. Adherence and survival properties of an epidemic methicillin-resistant strain of Staphylococcus aureus compared with those of methicillin-sensitive strains.  J Med Microbiol. 1990;  32 195-200
  PubMedGoogle Scholar
• 30 Ellis M W, Hospenthal D R, Dooley D P et al.. Natural history of community-acquired methicillin-resistant Staphylococcus aureus colonization and infection in soldiers.  Clin Infect Dis. 2004;  39 971-979
  CrossrefPubMedGoogle Scholar
• 31 Cosgrove S E, Carmeli Y. The impact of antimicrobial resistance on health and economic outcomes.  Clin Infect Dis. 2003;  36 1433-1437
  CrossrefPubMedGoogle Scholar
• 31a Mc Cabe W R, Jackson G G. Gram-negative bacteremia.  Arch Intern Med. 1962;  110 847-864
  PubMedGoogle Scholar
• 32 Charlson M E, Pompei P, Ales K L et al.. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation.  J Chronic Dis. 1987;  40 373-383
  CrossrefPubMedGoogle Scholar
• 33 Levine D P, Fromm B S, Reddy B R. Slow response to vancomycin or vancomycin plus rifampin in methicillin-resistant Staphylococcus aureus endocarditis.  Ann Intern Med. 1991;  115 674-680
  CrossrefPubMedGoogle Scholar
• 34 Cruciani M, Gatti G, Lazzarini L et al.. Penetration of vancomycin into human lung tissue.  J Antimicrob Chemother. 1996;  38 865-869
  PubMedGoogle Scholar
• 35 Lamer C, de Beco V, Soler P et al.. Analysis of vancomycin entry into pulmonary lining fluid by bronchoalveolar lavage in critically ill patients.  Antimicrob Agents Chemother. 1993;  37 281-286
  PubMedGoogle Scholar
• 36 Rodman D P, McKnight J T, Rogers T et al.. The appropriateness of initial vancomycin dosing.  J Fam Pract. 1994;  38 473-477
  PubMedGoogle Scholar
• 37 Conte Jr J E, Golden J A, Kipps J et al.. Intrapulmonary pharmacokinetics of linezolid.  Antimicrob Agents Chemother. 2002;  46 1475-1480
  CrossrefPubMedGoogle Scholar
• 38 Wunderink R G, Rello J, Cammarata S K et al.. Linezolid vs vancomycin: analysis of two double-blind studies of patients with methicillin-resistant Staphylococcus aureus nosocomial pneumonia.  Chest. 2003;  124 1789-1797
  CrossrefPubMedGoogle Scholar
• 39 Stevens D L, Herr D, Lampiris H et al.. Linezolid versus vancomycin for the treatment of methicillin-resistant Staphylococcus aureus infections.  Clin Infect Dis. 2002;  34 1481-1490
  CrossrefPubMedGoogle Scholar
• 40 Levin A S, Barone A A, Penco J et al.. Intravenous colistin as therapy for nosocomial infections caused by multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii .  Clin Infect Dis. 1999;  28 1008-1011
  PubMedGoogle Scholar
• 41 Kang C I, Kim S H, Park W B et al.. Bloodstream infections caused by antibiotic-resistant gram-negative bacilli: risk factors for mortality and impact of inappropriate initial antimicrobial therapy on outcome.  Antimicrob Agents Chemother. 2005;  49 760-766
  CrossrefPubMedGoogle Scholar
• 42 Roghmann M C. Predicting methicillin resistance and the effect of inadequate empiric therapy on survival in patients with Staphylococcus aureus bacteremia.  Arch Intern Med. 2000;  160 1001-1004
  CrossrefPubMedGoogle Scholar
• 43 Gonzalez C, Rubio M, Romero-Vivas J et al.. Bacteremic pneumonia due to Staphylococcus aureus: a comparison of disease caused by methicillin-resistant and methicillin-susceptible organisms.  Clin Infect Dis. 1999;  29 1171-1177
  CrossrefPubMedGoogle Scholar
• 44 Kollef M H, Sherman G, Ward S et al.. Inadequate antimicrobial treatment of infections: a risk factor for hospital mortality among critically ill patients.  Chest. 1999;  115 462-474
  CrossrefPubMedGoogle Scholar
• 45 Lentino J R, Hennein H, Krause S et al.. A comparison of pneumonia caused by gentamicin, methicillin-resistant and gentamicin, methicillin-sensitive Staphylococcus aureus: epidemiologic and clinical studies.  Infect Control. 1985;  6 267-272
  PubMedGoogle Scholar
• 46 Combes A, Luyt C E, Fagon J Y et al.. Impact of methicillin resistance on outcome of Staphylococcus aureus ventilator-associated pneumonia.  Am J Respir Crit Care Med. 2004;  170 786-792
  CrossrefPubMedGoogle Scholar
• 47 Zahar J R, Clec'h C, Tafflet M et al.. Is methicillin resistance associated with a worse prognosis in Staphylococcus aureus ventilator-associated pneumonia?.  Clin Infect Dis. 2005;  41 1224-1231
  CrossrefPubMedGoogle Scholar
• 48 Shorr A F, Combes A, Kollef M H et al.. Methicillin resistant Staphylococcus aureus prolongs intensive care unit length of stay in ventilator-associated pneumonia despite initially appropriate antibiotic therapy.  Crit Care Med. 2005;  , In press
  PubMedGoogle Scholar
• 49 Chastre J, Wolff M, Fagon J Y et al.. Comparison of 8 vs 15 days of antibiotic therapy for ventilator-associated pneumonia in adults: a randomized trial.  JAMA. 2003;  290 2588-2598
  CrossrefPubMedGoogle Scholar
• 50 Luyt C E, Combes A, Trouillet J L et al.. Impact of piperacillin resistance on the outcome of Pseudomonas aeruginosa ventilator-associated pneumonia [abstract].  Am J Respir Crit Care Med. 2005;  171 A819
  PubMedGoogle Scholar

Alain CombesM.D. 

Service de Réanimation Médicale, Pr Gibert, Institut de Cardiologie, Groupe Hospitalier Pitié-Salpêtrière

47 boulevard de l'Hôpital, 75651 Paris Cedex 13, France

Email: alain.combes@psl.aphp.fr